

# Review of pramlintide as adjunctive therapy in treatment

Drug Design, Development and Therapy  
2, 203

DOI: [10.2147/dddt.s3225](https://doi.org/10.2147/dddt.s3225)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Special Considerations with Insulin Therapy in Older Adults with Diabetes Mellitus. <i>Drugs and Aging</i> , 2011, 28, 429-438.	1.3	10
2	A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 911-920.	2.2	38
3	ADA-EASD diabetes guidance: individualised treatment of hyperglycaemia. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 146-151.	0.6	8
4	History of current non-insulin medications for diabetes mellitus. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2012, 2, 19081.	0.4	56
5	The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development. <i>Drug Discovery Today</i> , 2012, 17, 1006-1014.	3.2	47
6	Polymeric particles for the controlled release of human amylin. <i>Colloids and Surfaces B: Biointerfaces</i> , 2012, 94, 101-106.	2.5	26
7	Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine. <i>Journal of Diabetes</i> , 2013, 20, 20-29.	0.8	20
8	Amylin Uncovered: A Review on the Polypeptide Responsible for Type II Diabetes. <i>BioMed Research International</i> , 2013, 2013, 1-17.	0.9	78
9	Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment. <i>Review of Diabetic Studies</i> , 2013, 10, 133-156.	0.5	104
10	Obesity Pharmacotherapy: Current Perspectives and Future Directions. <i>Current Cardiology Reviews</i> , 2013, 9, 33-54.	0.6	16
11	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. <i>Contemporary Diabetes</i> , 2014, , 239-278.	0.0	0
12	Type 1 diabetes. <i>Lancet, The</i> , 2014, 383, 69-82.	6.3	1,863
13	Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats. <i>European Journal of Pharmacology</i> , 2014, 737, 91-96.	1.7	16
14	Emerging treatments for post-transplantation diabetes mellitus. <i>Nature Reviews Nephrology</i> , 2015, 11, 465-477.	4.1	62
15	Postprandial dysmetabolism: Too early or too late?. <i>Hormones</i> , 2016, 15, 321-344.	0.9	24
16	A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. <i>British Journal of Pharmacology</i> , 2017, 174, 591-602.	2.7	45
17	Therapeutic molecules against type 2 diabetes: What we have and what are we expecting?. <i>Pharmacological Reports</i> , 2017, 69, 959-970.	1.5	31
18	Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E598-E607.	1.8	27

#	ARTICLE	IF	CITATIONS
19	The application of sulfur-containing peptides in drug discovery. Chinese Chemical Letters, 2018, 29, 1079-1087.	4.8	66
20	Adjunctive therapy for glucose control in patients with type 1 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 159-173.	1.1	19
21	Pathophysiology of Type 2 Diabetes. , 2019, , 101-116.		0
22	GPCR targets in type 2 diabetes. , 2020, , 367-391.		2
23	Role of Glucagon in Automated Insulin Delivery. Endocrinology and Metabolism Clinics of North America, 2020, 49, 179-202.	1.2	16
24	Analysis of Prairie Vole Amylin Reveals the Importance of the N-Terminus and Residue 22 in Amyloidogenicity and Cytotoxicity. Biochemistry, 2020, 59, 471-478.	1.2	5
25	Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss. Journal of Pharmacology and Experimental Therapeutics, 2020, 373, 269-278.	1.3	13
26	Targeting Human Islet Amyloid Polypeptide Aggregation and Toxicity in Type 2 Diabetes: An Overview of Peptide-Based Inhibitors. Chemical Research in Toxicology, 2020, 33, 2719-2738.	1.7	15
27	SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 21-29.	0.3	0
28	Analysis of Amylin Consensus Sequences Suggests That Human Amylin Is Not Optimized to Minimize Amyloid Formation and Provides Clues to Factors That Modulate Amyloidogenicity. ACS Chemical Biology, 2020, 15, 1408-1416.	1.6	7
29	Recent Advances in Insulin Therapy. Diabetes Technology and Therapeutics, 2020, 22, 929-936.	2.4	19
30	Analysis of Proline Substitutions Reveals the Plasticity and Sequence Sensitivity of Human IAPP Amyloidogenicity and Toxicity. Biochemistry, 2020, 59, 742-754.	1.2	9
31	The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 74-83.	1.3	18
32	Challenge of diabetes mellitus and researchersâ€™ contributions to its control. Open Chemistry, 2021, 19, 614-634.	1.0	0
33	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Frontiers in Endocrinology, 2020, 11, 617400.	1.5	25
34	The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complementarily on body weight reduction and metabolic profile. BMC Endocrine Disorders, 2021, 21, 10.	0.9	15
35	Safety, tolerability and pharmacokinetic characterisation of DACRA KBPâ€™042 in healthy male subjects. British Journal of Clinical Pharmacology, 2021, , .	1.1	7
36	Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. P and T, 2018, 43, 214-227.	1.0	3

#	ARTICLE	IF	CITATIONS
38	Pramlintide for <sc>postâ€bariatric</sc> hypoglycaemia. Diabetes, Obesity and Metabolism, 2022, 24, 1021-1028.	2.2	4
39	Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide. Pharmaceutics, 2022, 14, 553.	2.0	3
40	Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Advanced Drug Delivery Reviews, 2022, 185, 114280.	6.6	32
41	Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine, 2022, 11, 2207.	1.0	9
42	Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles. Research in Pharmaceutical Sciences, 2022, 17, 594.	0.6	1
43	Does receptor balance matter? â€ Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine and Pharmacotherapy, 2022, 156, 113842.	2.5	6
45	Pathophysiology of Type 2 Diabetes. , 2023, , 127-142.		0